摘要
作者在国内首先制备了骨钙素(BGP)的抗血清,建立了BGP放射免疫测定方法。该抗血清特异性和灵敏度高,其最小检出量IC_(50)为2.5μg/L,批内差异<2.5％,批间差异<10.0％。应用本法测定了338例正常人和100例骨质疏松、糖尿病、卵巢切除、骨肿瘤、慢性肾功能衰竭、佝偻病和甲状旁腺功能亢进症患者血清BGP水平。骨质疏松BGP水平大多数下降,甲状旁腺功能亢进症、骨肿瘤者则明显升高,因此,血清BGP放免测定是骨病、代谢性骨病诊断和研究的一个重要检测手段。
We produced BGP-antiserum, and developed the BGP RIA. This method was specific and sensitive for the detection of BGP. The intra-and inter-assay CV were less than 2.5% and 10% respectively. We determined BGP level in 338 normal subjects and 100 patients with various diseases, such as: osteoporosis, diabetes mellitus, post-ccphorectcmy, bone tumor, chronic renal failure,hyperparathyroidism and rickets. We found the BGP level in the patients with osteoporosis . was decreased, but those with hyperparathyroidism and bone tumor were significantly increased. So BGP RIA is an important method for diagnosing ostyeopathy and metabolic bone disease.
出处
《中华内分泌代谢杂志》
CAS
CSCD
北大核心
1991年第2期87-89,共3页
Chinese Journal of Endocrinology and Metabolism
关键词
骨钙素
放射免疫测定
代谢性骨病
Osteocalcin Radioimmunoassay Bone disease, metabolic
